Maravai LifeSciences Holdings, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-12.4M | $-3.7M | $-35.7M | $-25.6M | $-39.6M | $-29.9M | $-25.9M | $-97.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $5.3M | $4.9M | $5.9M | $6.0M | $6.0M | $5.7M | $5.5M | $5.0M |
| Amortization | $6.5M | $6.5M | $6.5M | $7.2M | $7.2M | $7.0M | $6.9M | $6.9M |
| Stock-Based Compensation | $10.2M | $6.7M | $3.9M | $9.1M | $6.8M | $10.4M | $10.5M | $13.1M |
| Net Cash from Operating Activities | $4.0M | $8.7M | $-22.8M | $-15.2M | $-10.3M | $-9.4M | $-14.6M | $13.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $370.0K | $4.4M | $2.1M | $3.7M | $2.9M | $4.5M | $5.8M | $8.6M |
| Business Acquisitions | $0 | $0 | $0 | $0 | $362.0K | $18.6M | $0 | $0 |
| Net Cash from Investing Activities | $-370.0K | $-4.4M | $-2.1M | $-2.9M | $-3.2M | $-23.1M | $-4.9M | $-9.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-99.0M | $-55.2M | $-1.8M | $-8.2M | $-1.5M | $-4.9M | $-236.2M | $809.0K |
| Net Change in Cash | $-95.3M | $-51.0M | $-26.7M | $-26.3M | $-15.1M | $-37.3M | $-255.8M | $5.0M |
| Free Cash Flow | $3.6M | $4.2M | $-24.9M | $-18.8M | $-13.1M | $-13.9M | $-20.5M | $4.5M |